Roche Fuzeon (T-20) supply
Roche and Trimeris are setting up 1,200-patient access program for HIV fusion inhibitor Fuzeon (T-20/enfuvirtide) in anticipation of supply constraints at time of launch. The program will commence in September/October and reach its patient cap by March 2003, Roche said. "In the short-term, we do not have the flexibility to increase production beyond our current capacity to meet a potentially higher than initially anticipated demand," Roche said. The companies will file Fuzeon in the third quarter and will receive a "fast-track" review. One estimate for expanded availability would have the company supplying 40,000 patients by end of 2004..
You may also be interested in...
Roche/Trimeris' 2003 production cap for Fuzeon includes doses for 12,000 to 15,000 patients, in addition to a six-month "safety supply," the companies said during a Dec. 18 analyst call
Roche and Trimeris file NDA for HIV fusion inhibitor Fuzeon (T-20/enfuvirtide) Sept. 17. The companies are establishing a 1,200-patient access program in anticipation of supply constraints (1"The Pink Sheet" Aug. 5, In Brief)...
AstraZeneca's CEO and other leaders from COVID-19 vaccine companies will face some tough questions in Brussels, but the European Commission wants to put differences behind it and solve the vaccine supply problem as soon as possible.